Great posts indeed!
I like comparing with Nanosonics as they have a unique medical device that's well patented. Interestingly CDX has more revenue than they did when they had an mcap of 180M. I think even now we are undervalued and should be over 15c.
If we can hit the numbers above, and use NAN as a comparable, that's a 2Bn mcap, or $2.22. NAN is a niche product for disinfection using high frequency sound waves (bacteria is literally shattered by noise with their product): the general consumer is unaware of this product. Conneqt will be a household name so I think there's also room for a premium on a PE filled by retail investors. IMO Cochlear has had a PE premium for many years, and it's still gone up since I looked at several years ago (it was 50).
Historical financials below.
Add to My Watchlist
What is My Watchlist?
